ScoreWhy is Alnylam Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 36.7%, the company declared Very Positive results in Dec 25
- OPERATING CASH FLOW(Y) Highest at USD 524.09 MM
- NET PROFIT(HY) Higher at USD 405.83 MM
- ROCE(HY) Highest at 73.28%
2
With ROE of 45.14%, it has a expensive valuation with a 53.59 Price to Book Value
- Over the past year, while the stock has generated a return of 16.99%, its profits have risen by 431.7% ; the PEG ratio of the company is 0.3
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -2.31% over the previous quarter and currently hold 1.73% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Alnylam Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Alnylam Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Alnylam Pharmaceuticals, Inc.
16.99%
2.78
41.05%
S&P 500
13.5%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
49.77%
EBIT Growth (5y)
21.11%
EBIT to Interest (avg)
-3.79
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
119
Industry P/E
Price to Book Value
53.59
EV to EBIT
84.00
EV to EBITDA
75.61
EV to Capital Employed
67.47
EV to Sales
11.34
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
80.33%
ROE (Latest)
45.14%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 524.09 MM
NET PROFIT(HY)
Higher at USD 405.83 MM
ROCE(HY)
Highest at 73.28%
INVENTORY TURNOVER RATIO(HY)
Highest at 8.46 times
NET SALES(Q)
At USD 1,097.03 MM has Grown at 36.7%
CASH AND EQV(HY)
Highest at USD 5,633.11 MM
-16What is not working for the Company
PRE-TAX PROFIT(Q)
At USD 25.65 MM has Fallen at -52.56%
NET PROFIT(Q)
At USD 50.93 MM has Fallen at -30.18%
RAW MATERIAL COST(Y)
Grown by 8.66% (YoY
INTEREST(Q)
Highest at USD 129.34 MM
Here's what is working for Alnylam Pharmaceuticals, Inc.
Net Sales
At USD 1,097.03 MM has Grown at 36.7%
over average net sales of the previous four periods of USD 802.52 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Inventory Turnover Ratio
Highest at 8.46 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Operating Cash Flow
Highest at USD 524.09 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Cash and Eqv
Highest at USD 5,633.11 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Alnylam Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 25.65 MM has Fallen at -52.56%
over average net sales of the previous four periods of USD 54.07 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Interest
At USD 129.34 MM has Grown at 191.31%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Net Profit
At USD 50.93 MM has Fallen at -30.18%
over average net sales of the previous four periods of USD 72.95 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Interest
Highest at USD 129.34 MM
in the last five periods and Increased by 191.31% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Raw Material Cost
Grown by 8.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Non Operating Income
Highest at USD 0.14 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
